Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer
Abstract Androgens are a major driver of prostate cancer (PCa) and continue to be a critical treatment target for advanced disease, which includes castration therapy and antiandrogens. However, resistance to these therapies leading to metastatic castration-resistant prostate cancer (mCRPC), and the...
Saved in:
Main Authors: | Madonna R. Peter, Misha Bilenky, Alastair Davies, Ruth Isserlin, Gary D. Bader, Neil E. Fleshner, Martin Hirst, Amina Zoubeidi, Bharati Bapat |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/8a0d4c3f1dab4fb8aab66b888d10d9ef |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
by: Nikolai A. Ognerubov
Published: (2021) -
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
by: Jingsong Zhang, et al.
Published: (2017) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
by: Faiza Naseer, et al.
Published: (2021) -
Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
by: Peter Arnold, et al.
Published: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016)